Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the gonadotropin releasing hormone receptor (GnRH-R).

@article{Pelletier2009DiscoveryO6,
  title={Discovery of 6-(\{4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl\}methyl)quinoxaline (WAY-207024): an orally active antagonist of the gonadotropin releasing hormone receptor (GnRH-R).},
  author={Jeffrey C. Pelletier and Murty V Chengalvala and Joshua E Cottom and Irene B. Feingold and Daniel M Green and Diane B Hauze and Christine A Huselton and James W Jetter and Gregory S. Kopf and Joseph T Lundquist and Ronald L. Magolda and Charles W Mann and John F Mehlmann and John F Rogers and Linda K Shanno and William R Adams and Cesario O Tio and Jay E. Wrobel},
  journal={Journal of medicinal chemistry},
  year={2009},
  volume={52 7},
  pages={2148-52}
}
A potent, highly insoluble, GnRH antagonist with a 2-phenyl-4-piperazinylbenzimidazole template and a quinoxaline-2,3-dione pharmacophore was modified to maintain GnRH antagonist activity and improve in vitro pharmaceutical properties. Structural changes to the quinoxaline-2,3-dione portion of the molecule resulted in several structures with improved properties and culminated in the discovery of 6-([4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl] methyl)quinoxaline (WAY-207024… CONTINUE READING